Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

consentis diagnostics gmbh (8164669) - gadotersäure - injektionslösung - teil 1 - injektionslösung; gadotersäure (26208) 279,32 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

consentis diagnostics gmbh (8164669) - gadotersäure - injektionslösung - teil 1 - injektionslösung; gadotersäure (26208) 279,32 milligramm

Österreich - Deutsch - Ecolab

ecolab deutschland gmbh -

Schweiz - Deutsch - OFAG-BLW (Bundesamt für Landwirtschaft)

bayer s.p.a. - propamocarb-hydrochlorid; fenamidon - 015877 - italien - fungizid ;

Schweiz - Deutsch - OFAG-BLW (Bundesamt für Landwirtschaft)

bayer sas - propamocarb-hydrochlorid; fenamidon - 2100017 - frankreich - fungizid ;

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fujisawa deutschland gmbh - carazolol - tablette - carazolol 5.mg

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

noridem enterprises ltd - fluconazol - fluconazol

Schweiz - Deutsch - OFAG-BLW (Bundesamt für Landwirtschaft)

compo jardin ag - propamocarb-hydrochlorid; fenamidon - scsuspensionskonzentrat - 33.5 %375 g/l; 6.7 %75 g/l; - fungizid ;

Europäische Union - Deutsch - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - mukoviszidose - andere produkte für die atemwege - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 und 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 und 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Europäische Union - Deutsch - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - mukoviszidose - andere produkte für die atemwege - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.